Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis

• Published in: Nanomedicine (London, England) Vol. 12; no. 11; pp. 1231 - 1242
• Main Authors: Pujol-Autonell, Irma, Mansilla, Maria-Jose, Rodriguez-Fernandez, Silvia, Cano-Sarabia, Mary, Navarro-Barriuso, Juan, Ampudia, Rosa-Maria, Rius, Aleix, Garcia-Jimeno, Sonia, Perna-Barrull, David, Martinez-Caceres, Eva, Maspoch, Daniel, Vives-Pi, Marta
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2017
• Subjects: Animals; Antigens; Apoptosis; Autoantigens - administration & dosage; Autoantigens - immunology; Autoantigens - therapeutic use; Autoimmune diseases; autoimmunity; Dendritic cells; Disease; experimental autoimmune encephalomyelitis; Female; Immunotherapy; Immunotherapy - methods; Lipids; liposomes; Liposomes - chemistry; Mice, Inbred C57BL; Multiple sclerosis; Multiple Sclerosis - immunology; Multiple Sclerosis - therapy; Myelin-Oligodendrocyte Glycoprotein - administration & dosage; Myelin-Oligodendrocyte Glycoprotein - immunology; Myelin-Oligodendrocyte Glycoprotein - therapeutic use; Peptides; Peptides - administration & dosage; Peptides - immunology; Peptides - therapeutic use; Phosphatidylserines - chemistry; Proteins; Rheumatoid arthritis; T-Lymphocytes, Regulatory - immunology; Tumor necrosis factor-TNF; United States > US; Spain; experimental autoimmune encephalomyelitis; autoimmunity; liposomes; multiple sclerosis; immunotherapy
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2016-0410

Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed and . Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25 FoxP3 CD4 T-cell subset. This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.